Table 4 Primary feasibility outcomes presented as proportions and percentages
Analysis | Articulation therapy | U-VBF therapy | ||
|---|---|---|---|---|
% | Proportions | % | Proportions | |
Recruitment rate | 40 | 8/20 | 55 | 11/20 |
Retention rate | 100 | 8/8 | 90.9 | 10/11 |
Baseline PCC | 75 | 6/8 | 80.8 | 9/11 |
Baseline CleftQ | 87.5 | 7/8 | 100 | 11/11 |
Baseline ICS | 100 | 8/8 | 100 | 11/11 |
Follow-up 1 PCC | 75 | 6/8 | 90.9 | 10/11 |
Follow-up 1 CleftQ | 100 | 8/8 | 90.9 | 10/11 |
Follow-up 1 ICS | 100 | 8/8 | 90.9 | 10/11 |
Follow-up 2 PCC | 87.5 | 7/8 | 80.8 | 9/11 |
Follow-up 2 Cleft Q | 87.5 | 7/8 | 90.9 | 10/11 |
Follow-up 2 ICS | 87.5 | 7/8 | 90.9 | 10/11 |
Follow-up 2 ESQ | 100 | 8/8 | 100 | 11/11 |
Follow-up 2 Intervention acceptability questionnaire | 87.5 | 7/8 | 90.9 | 10/11 |
Therapy session 1 PCC completed | 100 | 8/8 | 81.8 | 9/11 |
Therapy session 2 PCC completed | 75 | 6/8 | 90.9 | 10/11 |
Therapy session 3 PCC completed | 100 | 8/8 | 100 | 11/11 |
Therapy session 4 PCC completed | 100 | 8/8 | 100 | 11/11 |
Therapy session 5 PCC completed | 87.5 | 7/8 | 80 | 8/10 |
Therapy session 6 PCC completed | 75 | 6/8 | 80 | 8/10 |
Therapy sessions, reaching dose 100 | 100 | 48/48 | 98.4 | 63/64 |
Within-therapy session completed dose recording | 87.5 | 42/48 | 96.9 | 62/64 |